Funding for this research was provided by:
Ministero della Salute (SG-2019-12370279)
Israel Cancer Research Fund (845755)
Received: 11 October 2021
Accepted: 15 June 2022
First Online: 15 July 2022
: The study protocol for the Italian samples was reviewed and approved by the Pisa University Hospital Ethics Committee (approval number 363/2014), and written informed consent was provided by each patient. The study for the Israeli samples was conducted according to the protocols approved by the Institutional Review Board at Hadassah Medical Center (HMO-14-0198), with procedures performed in accordance with the Declaration of Helsinki. Blood and tissue samples were obtained from donors who have provided written informed consent.
: Not applicable
: BPB, EK, SO, FM, and SGC are inventors on IP filings of this work by the Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. BPB and SO receive research funding from Volition Belgium Rx for an unrelated study.